New Zealand markets close in 4 hours 1 minute

Boston Scientific Corporation (BSX)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
68.07-0.77 (-1.12%)
At close: 04:00PM EDT
68.17 +0.10 (+0.15%)
After hours: 07:40PM EDT

Boston Scientific Corporation

300 Boston Scientific Way
Marlborough, MA 01752-1234
United States
508 683 4000
https://www.bostonscientific.com

Sector(s)Healthcare
IndustryMedical Devices
Full-time employees48,000

Key executives

NameTitlePayExercisedYear born
Mr. Michael F. MahoneyChairman, President & CEO4.83M12.98M1965
Mr. Daniel J. BrennanExecutive VP & CFO2.15M1.71M1966
Mr. Joseph M. FitzgeraldExecutive VP & Group President of Cardiology1.84M4.7M1964
Mr. Jeffrey B. MirvissExecutive VP & President of Peripheral Interventions1.44MN/A1966
Mr. Arthur Crosswell ButcherExecutive VP and Group President of MedSurg & Asia Pacific1.49M626.04k1971
Mr. David J. RouxIndependent Director135kN/A1957
Mr. John Bradley SorensonExecutive Vice President of Global OperationsN/AN/A1968
Ms. Emily WoodworthSenior VP, Global Controller & Chief Accounting OfficerN/AN/A1978
Ms. Jodi Euerle EddySenior VP and Chief Information & Digital OfficerN/AN/A1974
Mr. Jonathan R MonsonSenior VP of Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Corporate governance

Boston Scientific Corporation’s ISS governance QualityScore as of 1 April 2024 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.